Sign in

CIK 0001658551 · Non-accelerated filer<br>Smaller reporting company

Amylyx Pharmaceuticals, Inc.

Sign in to watch
Ticker
AMLX
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
DE
Entity type
operating
EIN
464600503
Phone
617-682-0917
Business address
55 CAMBRIDGE PARKWAY, SUITE 6W, CAMBRIDGE, MA, 02142
Open-market buys, last 90 days
$0
in 0 filings
Open-market sales, last 90 days
$10,951,125
in 9 filings, $8.0M under 10b5-1 plans

Net −$10,951,125. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.

Pace of trading Bought Sold

Who's trading

90 days

  1. Cohen Joshua B −$4.0M Co-Chief Executive Officer sold 4% of stake
  2. Klee Justin B. −$4.0M Co-Chief Executive Officer sold 4% of stake
  3. FRATES JAMES M −$1.6M Chief Financial Officer sold 18% of stake
  4. MILNE GEORGE M JR −$831K Director sold 4% of stake
  5. Bedrosian Camille L −$325K Chief Medical Officer sold 3% of stake
Date Insider Transaction Shares Price Value Owned after
2022-01-06 Cheng Isaac Director Conversion · Series B Preferred Stock −6,410,964 0
2022-01-06 Cheng Isaac Director Conversion · Series C-1 Preferred Stock −974,107 0
2022-01-06 Cheng Isaac Director Conversion · Series C-2 Preferred Stock −1,621,544 0
2022-01-06 Cheng Isaac Director Grant or award · Stock Option (Right to Buy) +8,400 8,400
2022-01-06 Yeramian Patrick D Chief Medical Officer Grant or award +28,333 206,333
2022-01-06 Yeramian Patrick D Chief Medical Officer Grant or award · Stock Option (right to buy) +127,500 127,500
2022-01-06 MILNE GEORGE M JR Director Purchase +26,315 $19.00 $500K 221,396
2022-01-06 MILNE GEORGE M JR Director Grant or award · Stock Option (Right to Buy) +8,400 8,400
2022-01-06 Cohen Joshua B Co-Chief Executive Officer Conversion +4,870 2,489,065
2022-01-06 Cohen Joshua B Co-Chief Executive Officer Grant or award +75,000 2,564,065
2022-01-06 Cohen Joshua B Co-Chief Executive Officer Conversion · Series C-1 Preferred Stock −4,870 0
2022-01-06 Cohen Joshua B Co-Chief Executive Officer Grant or award · Stock Option (right to buy) +337,500 337,500
2022-01-06 Quimi Daphne Director Grant or award · Stock Option (Right to Buy) +8,400 8,400
2022-01-06 Olinger Margaret Chief Commercial Officer Grant or award +28,333 209,916
2022-01-06 Olinger Margaret Chief Commercial Officer Purchase +6,842 $19.00 $130K 216,758
2022-01-06 Olinger Margaret Chief Commercial Officer Grant or award · Stock Option (right to buy) +127,500 127,500
2022-01-06 FRATES JAMES M Chief Financial Officer Grant or award +31,667 31,667
2022-01-06 FRATES JAMES M Chief Financial Officer Grant or award · Stock Option (right to buy) +142,500 142,500
2022-01-06 Klee Justin B. Co-Chief Executive Officer Conversion +4,870 2,489,065
2022-01-06 Klee Justin B. Co-Chief Executive Officer Grant or award +75,000 2,564,065

Page 18 of 19 · 362 trades